Hirotsugu Shiroma

Hirotsugu Shiroma

Auto-generated profile, based on publicly available information

Hirotsugu Shiroma

School of Life Science and Technology, Tokyo Institute of Technology, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
AUAtsushi Ueda
Atsushi Ueda
SSShoji Shinkai
Shoji Shinkai
HSHirotsugu Shiroma
Hirotsugu Shiroma
YTYu Taniguchi
Yu Taniguchi
STSayaka Tsuchida
Sayaka Tsuchida
TYTakuji Yamada
Takuji Yamada
Evidence linking the gut-brain axis to Alzheimer’s disease (AD) is accumulating, but the characteristics of causally important microbes are poorly understood. We perform a fecal microbiome analysis in healthy subjects and those with mild cognitive impairment (MCI) and AD. We find that Faecalibacterium prausnitzii (F. prausnitzii) correlates with cognitive scores and decreases in the MCI group compared with the healthy group. Two isolated strains from the healthy group, live Fp360 and pasteurized Fp14, improve cognitive impairment in an AD mouse model. Whole-genome comparison of isolated strains reveals specific orthologs that are found only in the effective strains and are more abundant in the healthy group compared with the MCI group. Metabolome and RNA sequencing analyses of mouse brains provides mechanistic insights into the relationship between the efficacy of pasteurized Fp14, oxidative stress, and mitochondrial function. We conclude that F. prausnitzii strains with these specific orthologs are candidates for gut microbiome-based intervention in Alzheimer's-type dementia.

26 April 2022 in mSystems
Verified
Journal Article
Open access
HSHirotsugu Shiroma
Hirotsugu Shiroma
SSSatoshi Shiba
Satoshi Shiba
PEPande Putu Erawijantari
Pande Putu Erawijantari
HTHiroyuki Takamaru
Hiroyuki Takamaru
MYMasayoshi Yamada
Masayoshi Yamada
TYTakuji Yamada
Takuji Yamada
The gut microbiome and metabolites are associated with CRC progression and carcinogenesis. Postoperative CRC patients are reported to be at an increased CRC risk; however, how gut microbiome and metabolites are related to CRC risk in postoperative patients remains only partially understood.

25 July 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
HSHirotsugu Shiroma
Hirotsugu Shiroma
YDYoussef Darzi
Youssef Darzi
ETEtsuko Terajima
Etsuko Terajima
ZNZenichi Nakagawa
Zenichi Nakagawa
HTHirotaka Tsuchikura
Hirotaka Tsuchikura
TYTakuji Yamada
Takuji Yamada
The human gut microbiota produces diverse, extensive metabolites that have the potential to affect host physiology. Despite significant efforts to identify metabolic pathways for producing these microbial metabolites, a comprehensive metabolic pathway database for the human gut microbiota is still lacking. Here, we present Enteropathway, a metabolic pathway database that integrates 3269 compounds, 3677 reactions, and 876 modules that were obtained from 1012 manually curated scientific literature. Notably, 698 modules of these modules are new entries and cannot be found in any other databases. The database is accessible from a web application (https://enteropathway.org) that offers a metabolic diagram for graphical visualization of metabolic pathways, a customization interface, and an enrichment analysis feature for highlighting enriched modules on the metabolic diagram. Overall, Enteropathway is a comprehensive reference database that can complement widely used databases, and a tool for visual and statistical analysis in human gut microbiota studies and was designed to help researchers pinpoint new insights into the complex interplay between microbiota and host metabolism.

28 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
HSHirotsugu Shiroma
Hirotsugu Shiroma
YDYoussef Darzi
Youssef Darzi
ETEtsuko Terajima
Etsuko Terajima
ZNZenichi Nakagawa
Zenichi Nakagawa
HTHirotaka Tsuchikura
Hirotaka Tsuchikura
TYTakuji Yamada
Takuji Yamada
The human gut microbiota produces diverse, extensive metabolites which have the potential to affect host physiology. Despite significant efforts to identify metabolic pathways for producing these microbial metabolites, a comprehensive metabolic pathway database for the human gut microbiota is still lacking. Here, we present Enteropathway, a metabolic pathway database that integrates 3,121 compounds, 3,460 reactions, and 837 modules that were obtained from 835 manually curated scientific literature. Notably, 757 modules of these modules are new entries and cannot be found in any other databases. The database is accessible from a web application ( https://enteropathway.org ) that offers a metabolic diagram for graphical visualization of metabolic pathways, a customization interface, and an enrichment analysis feature for highlighting enriched modules on the metabolic diagram. Overall, Enteropathway is a comprehensive reference database and a tool for visual and statistical analysis in human gut microbiota studies and was designed to help researchers pinpoint new insights into the complex interplay between microbiota and host metabolism.

15 April 2021 in Research Square
Verified
Preprint
Open access
PDF file
HSHirotsugu Shiroma
Hirotsugu Shiroma
SSSatoshi Shiba
Satoshi Shiba
PEPande Putu Erawijantari
Pande Putu Erawijantari
HTHiroyuki Takamaru
Hiroyuki Takamaru
MYMasayoshi Yamada
Masayoshi Yamada
TYTakuji Yamada
Takuji Yamada
Background: Postoperative colorectal cancer (CRC) patients are at increased risk of developing metachronous CRC. Despite accumulating evidence indicating that the gut microbiota and metabolites can promote CRC carcinogenesis, the influence of surgery for CRC on the gut microbiota and metabolites remains partially understood. We hypothesized that if surgery does not eliminate the bacteria and metabolites promoting CRC carcinogenesis, these bacteria and metabolites might be associated with the development of metachronous CRC. To test this hypothesis, we collected 170 fecal samples from 85 CRC patients in pre- and approximately one year postsurgery status, and performed shotgun metagenomics sequencing and capillary electrophoresis time-of-flight mass spectrometry-based metabolomics analyses and compared pre- and postsurgery status.Results: CRC-associated bacteria such as Parvimonas micra and Fusobacterium nucleatum were significantly (P < 0.005) decreased after surgery. On the other hand, cholate, carcinogenesis-associated deoxycholate, its biotransformed genes (bai operon) from cholate to deoxycholate, and the contributing bacterium (Clostridium scindens) were significantly (P < 0.005) increased. Additionally, these alterations were only observed in postleft surgery. Cholate and glycocholate were significantly (P < 0.005) increased in postright surgery. We also developed a method for potential CRC risk assessment based on the gut microbiota and metabolomic compositions using a random forest machine learning algorithm and then applied it to postoperative patients. The estimated CRC risk based on the random forest algorithm was partially restored postsurgery. Conclusions: Our results indicate that the high potential CRC risk in CRC postoperative patients is associated with metabolites derived from the gut microbiota, which targets interventions to reduce the CRC risk.